

# Mounting Pressure on FDA Over Abortion Pill Approval Exposes the Dangers of Bureaucratic Discretion  

Earlier this month, the FDA approved a third mifepristone product for the U.S. market.

October 23, 2025 • News Releases 

Earlier this month, the FDA authorized the marketing of a second generic version of mifepristone. It approved the first generic in 2019. Prominent [GOP figures](https://thedispatch.com/article/generic-mifepristone-fda-republicans/) quickly urged President Donald Trump’s administration to reverse the decision. Cato’s [Jeffrey A. Singer](https://www.cato.org/people/jeffrey-singer) argues this reflects the politicization of drug regulation and highlights how the FDA’s broad discretion can be dangerously influenced by political pressures.

Singer [points out](https://www.cato.org/blog/when-fda-becomes-political-patients-autonomy-suffers) that: *“Regardless of one’s personal views on abortion the FDA’s decision to reopen a safety review of mifepristone reflects political pressure rather than scientific evidence. Once a brand-name drug has been demonstrated to be safe and effective, any chemically identical generic must be treated equivalently.*

*While the example involves a specific medication, the concern applies broadly to all drugs: political interference should never restrict access to treatments that are already proven safe and effective.* *This action underscores the risks inherent in maintaining the FDA’s monopoly over drug approval, which can limit medical autonomy and undermine public confidence in regulatory decisions”*

You can read more from Singer on this topic here: [https://​www​.cato​.org/​b​l​o​g​/​w​h​e​n​-​f​d​a​-​b​e​c​o​m​e​s​-​p​o​l​i​t​i​c​a​l​-​p​a​t​i​e​n​t​s​-​a​u​t​o​n​o​m​y​-​s​u​ffers](https://www.cato.org/blog/when-fda-becomes-political-patients-autonomy-suffers)

To reach Singer, please feel free to contact Emily Salamon at [esalamon@​cato.​org](mailto:esalamon@cato.org)

[![Creative Commons License](/build/cato_2020/images/creative-commons.svg)](http://creativecommons.org/licenses/by-nc-sa/4.0/) 
This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).